Goettingen, Germany and Aubagne, France , October 23, 2012 / B3C newswire / - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, has appointed its biopharmaceutical expert Stefan Schlack as Senior Vice President of Marketing. In his new position, Schlack, who is an experienced Sartorius employee, will assume responsibility for all marketing and product management activities.
Stefan Schlack holds a university degree in business management and has been working for Sartorius since 1996. After completing vocational training in industrial business management at Sartorius, he studied business economics and management in Cologne, Germany, and worked in field sales in the Sartorius laboratory business unit during his studies. After earning his university degree, Schlack relocated to the USA, where he worked as a key account manager, supporting pharmaceutical customers and handling OEM business. Upon his return to Sartorius headquarters in Goettingen in 2006, he was assigned responsibility for global key account management, covering international pharmaceutical companies. Since 2008, Stefan Schlack has been in charge of key account management as Vice President.
Current image file:
Stefan Schlack, Senior Vice President of Marketing at Sartorius Stedim Biotech:
http://www.sartorius.com/fileadmin/media/global/company/stefan_schlack.jpg
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs more than 2,800 people, and in 2011 earned sales revenue of 477.3 million euros.
Contact
Sartorius Stedim Biotech
Dominic Grone
Group Corporate Communications
+49(0)551.308.3324
dominic.grone@sartorius.com
